Complete Monthly Cost Analysis: Wegovy vs Mounjaro
Wegovy vs Mounjaro Monthly Cost Structure Differences
The monthly cost comparison between Wegovy and Mounjaro reveals distinct pricing patterns that impact your long-term budget planning. Wegovy follows a structured 16-week dose escalation protocol, with monthly costs ranging from £79.99 in month one to £209.99 at the maintenance 2.4mg dose. This predictable escalation allows for clear financial planning throughout your weight management journey. Mounjaro utilises a different dosing schedule and pricing structure, making direct monthly comparisons complex without considering your specific prescribed pathway.
Both Wegovy and Mounjaro represent significant monthly investments in your health, requiring careful consideration of ongoing costs versus potential benefits. The key difference lies in their escalation timelines and maintenance dose requirements. Wegovy reaches its maintenance dose at week 17, meaning your monthly cost stabilises at £209.99 from month five onwards. Understanding these cost patterns helps you choose between treatments based on both clinical suitability and financial sustainability over the long term.
Wegovy Monthly Pricing Breakdown: Start to Maintenance
Wegovy's monthly cost structure follows a transparent escalation pattern designed to minimise side effects while optimising effectiveness. Month one costs £79.99 for the 0.25mg starter dose, progressing to £94.99 in month two (0.5mg), £99.99 in month three (1mg), and £139.99 in month four (1.7mg). From month five onwards, the maintenance 2.4mg dose costs £209.99 monthly, representing your ongoing investment in weight management. Our bundle options provide convenience and supply security, with the Ultimate Stability Trio offering three months of maintenance supply for £649.99.
The total cost for your first four months of Wegovy escalation reaches £414.96, before settling into the monthly maintenance rhythm. New customers benefit from the FIRST40 discount code applied at checkout, while returning customers use DOSE25 to maintain competitive pricing. This transparent pricing structure eliminates surprises and allows accurate annual budgeting, with maintenance dose annual costs approximating £2,519.88. The predictable monthly investment supports long-term treatment planning alongside your healthcare provider's guidance.
Clinical Evidence Supporting Wegovy and Mounjaro Investment
The monthly cost of Wegovy and Mounjaro treatments reflects their robust clinical evidence base and potential health benefits. In the STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, as reported by Wilding et al., NEJM, 2021. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, suggesting potential long-term health value beyond weight management.
Mounjaro's dual GIP and GLP-1 receptor agonist mechanism offers a different clinical profile, with its own supporting evidence base for weight management outcomes. When evaluating monthly costs, consider that both treatments may help reduce long-term healthcare expenses through improved weight-related health markers. The prescription-only nature of both medications ensures proper medical supervision, with regular monitoring supporting both safety and effectiveness throughout your treatment journey.
How Wegovy and Mounjaro Work: Understanding Your Monthly Investment
Your monthly investment in Wegovy supports a sophisticated GLP-1 receptor agonist mechanism that mimics natural fullness hormones produced in your intestines. This prescription-only medicine works by reducing appetite, promoting feelings of fullness after smaller meals, and may help reduce food cravings by acting on brain appetite centres. The once-weekly FlexTouch pen delivers consistent medication levels, requiring the structured dose escalation that determines your monthly costs. Mounjaro operates through dual GIP and GLP-1 receptor agonism, offering a different mechanism that may appeal to certain patients based on their clinical profile. Both treatments require commitment to lifestyle changes including a reduced-calorie diet and increased physical activity, making the monthly investment part of a comprehensive approach to sustainable weight management.
Streamlined Ordering Process for Wegovy and Mounjaro
Accessing either Wegovy or Mounjaro through EverydayMeds involves a straightforward three-step process that respects the prescription-only nature of both treatments. Complete our three-minute online clinical assessment, providing accurate health information that enables proper prescriber evaluation of your suitability for either medication. Our qualified prescribers review your assessment within three working days (or 24 hours with express service), ensuring appropriate medical oversight of your treatment selection. Once approved, your medication ships via next-day cold-chain delivery, maintaining the temperature-controlled storage essential for both treatments. This efficient process minimises delays in starting your treatment while maintaining the medical safeguards required for prescription-only medicines. Regular follow-up assessments support ongoing treatment monitoring and dose adjustments as needed throughout your journey.
Storage Requirements and Practical Considerations
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, but their room temperature tolerances differ significantly and may influence your treatment choice. Wegovy tolerates up to six weeks at room temperature below 30°C once removed from the fridge, offering superior travel flexibility compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design used for Wegovy provides intuitive administration, with clear dose escalation markings that correspond to your monthly cost progression. Both treatments utilise pre-filled pens that eliminate dosing errors and ensure accurate medication delivery. Understanding these practical differences helps justify the monthly investment by ensuring you can maintain treatment consistency regardless of your lifestyle demands. Proper storage protects your monthly medication investment and maintains therapeutic effectiveness throughout the treatment period.
Annual Cost Planning for Wegovy vs Mounjaro Maintenance
Long-term financial planning for Wegovy and Mounjaro requires understanding both treatments' annual maintenance costs after completing initial escalation phases. Wegovy's maintenance dose represents an annual investment of approximately £2,519.88 at the 2.4mg monthly dose, providing predictable budgeting once you reach week 17. This stable monthly cost structure eliminates financial uncertainty and supports treatment adherence through consistent pricing. Mounjaro's annual maintenance costs follow a different pattern based on your prescribed maintenance dose and individual response profile.
Both treatments qualify as long-term commitments, with clinical evidence suggesting that discontinuation may lead to weight regain over time. The STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that monthly costs represent ongoing investment rather than temporary expense. Planning for sustained treatment helps optimise both clinical outcomes and cost-effectiveness of your chosen therapy, making the monthly investment a calculated health decision rather than discretionary spending.
Treatment Selection Support and Next Steps
Choosing between Wegovy and Mounjaro extends beyond monthly cost comparison to include clinical suitability, lifestyle factors, and individual response patterns. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your medical profile and financial preferences. Our clinical team considers factors including your medical history, current medications, and treatment goals when recommending between these options. The monthly cost difference may influence your decision, but clinical appropriateness remains the primary consideration for prescription-only medicines.
Ready to start your weight management journey with transparent monthly pricing? Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment, with new customer discount code FIRST40 and returning customer code DOSE25 applied at checkout. Our GPhC-registered pharmacy #9012878 ensures you receive genuine medications with full clinical support throughout your treatment. Take the first step towards sustainable weight management with clear understanding of your monthly investment and ongoing support from qualified healthcare professionals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
